ReviewFrontiers in immunology2026
B cells in acquired aplastic anemia and the exploratory role of rituximab: considerations in pediatric and female patients.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aplastic anemia (AA) is a severe hematological disorder characterized by bone marrow failure and peripheral pancytopenia. Immune dysregulation plays a central role in its pathogenesis. Recent studies highlight the critical involvement of activated B cells in the immunopathology of AA, influencing both disease onset and progression. Rituximab, a monoclonal antibody targeting CD20, demonstrates therapeutic potential by modulating B cell function. Notably, immune responses and clinical manifestations differ between pediatric and female patients, affecting the efficacy and safety profile of rituximab. This narrative review synthesizes current knowledge on B-cell involvement in AA, summarizes population-specific immunologic features, and appraises the exploratory evidence regarding rituximab use. By integrating mechanistic insights with available clinical observations, we highlight key gaps in the literature and outline priorities for future research to inform more individualized immunomodulatory strategies in AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.